Trulicity (dulaglutide) and Victoza (liraglutide) are prescription drugs prescribed to lower blood sugar levels and certain cardiovascular risks. Both drugs come as liquid solutions that are given as ...

The Food and Drug Administration (FDA) has approved Trulicity (dulaglutide; Eli Lilly) pen as adjunct to diet and exercise to improve glycemic control in in adults with type 2 diabetes. Dulaglutide, a ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Some of the Trulicity app’s features include medication reminders, a virtual demo of the Trulicity pen, live chats to answer questions in real-time, videos, and access to a savings card. To have a ...

INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...

Trulicity is a prescription drug used to help manage blood sugar levels and lower the risk of heart problems in certain adults. It is available as a liquid solution in prefilled injection pens.

Eli Lilly has launched its once-weekly diabetes therapy Trulicity in the US, hoping to break into the fast growing, competitive GLP-1 agonist market. Trulicity (dulaglutide) was approved by the FDA at ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...

The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of ...